Jacobs Engineering Group has been selected to provide engineering, procurement and construction management services for Novartis Pharma‘s estimated $100 million biotechnology center expansion project in France.
Novartis Pharma aims to increase its biotechnology center’s production capacity by 70 percent and build a second line of purification to manufacture multiple drugs at the same time, Jacobs said Thursday.
The project is set for completion in four years with the goal to add cell culture bioreactors to the site in addition to the production facilities for monoclonal antibodies from mammalian cells.
“We look forward to partnering with Novartis on the expansion of its Huningue site,†said Robert Norfleet, Jacobs senior vice president of life sciences.